SNY Earnings Date: Jan 28, 2027 (Estimated) — Sanofi
NASDAQ · Healthcare · Drug Manufacturers - General
Updated
When is SNY's next earnings date?
Sanofi (SNY) is expected to report Q4 2026 earnings on Thursday, January 28, 2027 at 1:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.01 on revenue of $14.44B.
How did SNY do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), Sanofi posted EPS of $4.02 versus the $1.63 estimate, a beat of 146.6%. Revenue was $16.36B against a $14.87B estimate.
How much does SNY stock move after earnings?
SNY beat EPS estimates in 5 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.3% (up or down) in the day after earnings.
About Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
🤖 AI Earnings Analysis
Sanofi is pursuing acquisitions to replenish its pipeline ahead of Dupixent’s eventual patent expiry, a necessary strategic move. Q3 revenue rose 13% to €16.4B, supporting a 10% 2026 growth outlook; results are strong, but deal execution matters.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | 1.63 | 4.02 | +146.63% | $16.36B | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 1.09 | 1.21 | +11.38% | $13.48B | ✅ Beat | -4.37% | -4.62% | -0.02% |
| 2026-04-23 | Q1 2026 | 1.06 | 1.10 | +3.77% | $12.31B | ✅ Beat | +1.35% | -1.84% | -0.40% |
| 2026-01-29 | Q4 2025 | 0.84 | 0.89 | +5.95% | $13.16B | ✅ Beat | +0.93% | +5.04% | +6.32% |
| 2025-10-24 | Q3 2025 | 1.60 | 1.70 | +6.31% | $14.54B | ✅ Beat | +4.28% | +2.88% | +0.23% |
| 2025-07-31 | Q2 2025 | 0.96 | 0.90 | — | $11.33B | ❌ Miss | -7.33% | -6.23% | +1.41% |
| 2025-04-24 | Q1 2025 | 0.95 | 0.94 | -0.95% | $10.41B | ❌ Miss | +0.97% | +3.62% | +2.16% |
| 2025-01-30 | Q4 2024 | 0.74 | 0.70 | -5.41% | $11.28B | ❌ Miss | +3.85% | +2.59% | +4.46% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q4 FY23 · $35.04B total
| Segment | Share | Revenue | YoY | Q4 FY22 | Q2 FY23 | Q4 FY23 |
|---|---|---|---|---|---|---|
| Reportable Geographical Zones | 65.3% | $22.88B | -1.4% | $23.21B | $20.19B | $22.88B |
| North America | 31.3% | $10.95B | -1.4% | $11.11B | $8.26B | $10.95B |
| FRANCE | 3.4% | $1.21B | +1.2% | $1.19B | $1.17B | $1.21B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.